ArticleWorld journal of gastrointestinal oncology2013
Complete remission of advanced hepatocellular carcinoma by sorafenib: A case report.
Article in World journal of gastrointestinal oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Review
- Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review.Clinical and molecular hepatology · 2017Review
- Long-term follow-up of complete remission of advanced hepatocellular carcinoma following sorafenib therapy: A case report.Oncology letters · 2017Article
- Deteriorated portal flow may cause liver failure in patients with hepatocellular carcinoma being treated with sorafenib.Journal of gastrointestinal oncology · 2016Article
- Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.Clinical and molecular hepatology · 2015Article
- Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy.World journal of gastroenterology · 2015Article
- Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib.European journal of medical research · 2015Review
- Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.World journal of gastroenterology · 2014Article
- Long-Term Maintenance of Complete Response after Sorafenib Treatment for Multiple Lung Metastases from Hepatocellular Carcinoma.Case reports in gastroenterologyArticle
- Hepatocellular Carcinoma with Distant Metastasis Cured by 20-Day Sorafenib Treatment.Case reports in gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the fifth most common malignant disease worldwide, and curative treatment remains difficult because the majority of cases are diagnosed in the advanced stage. Sorafenib is the only known effective systemic treatment, but patients rarely achieve complete remission (CR). A 66-year-old man with a history of alcoholic liver cirrhosis with a diagnosis of advanced HCC, was initially treated with transarterial chemoembolization on four occasions. However, the disease progressed with portal vein thrombosis. Therefore, sorafenib was started, and 4 mo later, the patient achieved CR. The treatment was continued for 12 mo, and CR was maintained up to 4 mo after sorafenib discontinuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.